Larimar Therapeutics, Inc. (LRMR) Income Statement
LRMR 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsLRMR revenue and net income
LRMR growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
LRMR quarterly EPS vs estimates
Larimar Therapeutics beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 4, 2026 (estimate $-0.35).
LRMR income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $350,000 | $318,000 | $311,000 | $272,000 | $326,000 | $155,000 | $78,000 | $261,000 | $188,000 | $212,000 |
| Gross profit | −$350,000 | −$318,000 | −$311,000 | −$272,000 | −$326,000 | −$155,000 | −$78,000 | −$261,000 | −$188,000 | −$212,000 |
| Research & development | $154.2M | $73.3M | $27.7M | $24.2M | $38.4M | $31.4M | $20.8M | $49.5M | $41.7M | $39.8M |
| Sales, general & admin | $18.3M | $17.6M | $14.1M | $12.3M | $12.1M | $11.4M | $2.4M | $1.5M | $12.4M | $18.3M |
| Total operating expenses | $172.5M | $90.9M | $41.8M | $36.5M | $50.5M | $42.8M | $23.2M | $62.5M | $53.7M | $56.9M |
| Operating income | −$172.5M | −$90.9M | −$41.8M | −$36.5M | −$50.5M | −$42.8M | −$23.2M | −$62.7M | −$53.9M | −$57.1M |
| Interest income | — | — | — | — | — | — | $248,000 | $246,000 | $971,000 | $347,000 |
| Interest expense | — | — | — | $318,000 | $326,000 | $0 | $1.8M | $246,000 | $971,000 | $347,000 |
| Income before taxes | −$165.7M | −$80.6M | −$36.9M | −$35.4M | −$50.6M | −$42.5M | −$23.1M | −$63.0M | −$52.9M | −$58.2M |
| Income taxes | — | — | — | −$1.2M | −$326,000 | −$155,000 | −$93,860 | −$1.6M | −$900,000 | −$300,000 |
| Net income | −$165.7M | −$80.6M | −$36.9M | −$34.2M | −$50.3M | −$42.3M | −$23.1M | −$61.4M | −$52.0M | −$57.9M |
| EBITDA | −$165.3M | −$80.3M | −$36.6M | −$36.2M | −$50.1M | −$42.6M | −$23.1M | −$60.8M | −$52.6M | −$57.4M |
| EPS (diluted) | −$2.21 | −$1.30 | −$0.85 | −$1.54 | −$2.97 | −$3.94 | −$13.20 | −$23.40 | −$22.92 | −$25.44 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $482,000 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | — | $87,000 | — | $87,000 | $88,000 | $241,000 | $74,000 | $87,000 | $80,000 | $81,000 | $69,000 |
| Gross profit | — | — | −$87,000 | — | −$87,000 | −$88,000 | $241,000 | −$74,000 | −$87,000 | −$80,000 | −$81,000 | −$69,000 |
| Research & development | $28.0M | $25.0M | $59.4M | $44.9M | $23.4M | $26.6M | $26.7M | $13.9M | $19.7M | $12.9M | $10.6M | $6.6M |
| Sales, general & admin | $6.4M | $6.1M | $4.6M | $4.7M | $4.4M | $4.6M | $4.6M | $4.3M | $5.0M | $3.8M | $3.5M | $3.8M |
| Total operating expenses | $34.4M | $31.1M | $64.0M | $49.5M | $27.8M | $31.2M | $31.3M | $18.3M | $24.6M | $16.7M | $14.1M | $10.3M |
| Operating income | −$34.4M | −$31.1M | −$64.0M | −$49.5M | −$27.8M | −$31.2M | −$31.3M | −$18.3M | −$24.6M | −$16.7M | −$14.2M | −$10.3M |
| Income before taxes | −$32.8M | −$29.6M | −$62.5M | −$47.7M | −$26.2M | −$29.3M | −$28.8M | −$15.5M | −$21.6M | −$14.7M | −$13.0M | −$9.1M |
| Income taxes | — | — | — | — | — | — | — | −$74,000 | — | $36,724 | $37,188 | −$76,000 |
| Net income | −$32.8M | −$29.6M | −$62.5M | −$47.7M | −$26.2M | −$29.3M | −$28.8M | −$15.5M | −$21.6M | −$14.7M | −$13.0M | −$9.1M |
| EBITDA | −$32.7M | −$29.5M | −$62.4M | −$47.6M | −$26.1M | −$29.2M | −$28.7M | −$15.4M | −$21.5M | −$14.6M | −$12.9M | −$9.0M |
| EPS (diluted) | −$0.30 | −$0.31 | −$0.73 | −$0.61 | −$0.41 | −$0.46 | −$0.45 | −$0.24 | −$0.34 | −$0.27 | −$0.30 | −$0.21 |
| Gross margin | — | — | — | — | — | — | 50.0% | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | −6,492.3% | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | −5,980.1% | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in LRMR's financial statements (latest annual report filed March 19, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
LRMR financial results
Larimar Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $165.7 million. Diluted earnings per share came to −$2.21.
See the LRMR stock overview for the latest quote and news, or the LRMR chart for price history and technical indicators.
LRMR income statement FAQ
Does Larimar Therapeutics have revenue?
Larimar Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Larimar Therapeutics profitable?
No. Larimar Therapeutics reported a net loss of $165.7 million in fiscal 2025.
How much does Larimar Therapeutics spend on research and development?
Larimar Therapeutics spent $154.2 million on research and development in fiscal 2025.
What are Larimar Therapeutics's earnings per share?
Larimar Therapeutics earned $-2.21 per diluted share in fiscal 2025, compared with $-1.30 a year earlier.
When will Larimar Therapeutics report its next earnings?
Larimar Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026.
When does Larimar Therapeutics's fiscal year end?
Larimar Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 19, 2026.